[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myositis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myositis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,46,92,126,150,194,221,255,287,324,347],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643873","phase-4-anti-inflammation-treatment-for-idiopathic-inflammatory-myopathies-100643873",false,"NCT07668505","Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies","A Novel Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies","Inclusion Criteria:\n\n1. ≥18 to \\\u003C80 years of age\n2. Myositis disease onset \\>18 years\n3. Fulfillment of 2017 American College of Rheumatology\u002FEuropean League Against Rheumatism (ACR\u002FEULAR) IIM classification criteria\n4. Active myositis defined as Manual Muscle Testing 8 (MMT8) score \\\u003C142 with at least two other abnormal International Myositis Assessment \\& Clinical Studies Group (IMACS) core set measures (Visual Analogue Scale (VAS) of patient global activity ≥2 cm, physician's global disease activity ≥2 cm, at least one muscle enzyme \\>1.5 times upper limit of normal, Health ssessment Questionnaire(HAQ) ≥0.25), despite 2 additional immunosuppressive treatments on top of glucocorticoids.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation,\n2. Malignancy\n3. Functional class 4\n4. Contraindication to Maraviroc.","ALL","18 Years","80 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn if the drug Maraviroc works to treat refractory idiopathic inflammatory myopathy (myositis) in patients who have not responded well to traditional therapies. It will also learn about how the drug affects muscle inflammation and function. The main questions it aims to answer are: Does Maraviroc reduce inflammation in the muscles? Does Maraviroc improve patients' muscle function and overall clinical symptoms? This is an open-label study, meaning researchers will give Maraviroc to all participants (there is no placebo) to see if the drug works to treat refractory myositis. Participants will: Take a 300mg Maraviroc tablet every day for 12 weeks. Undergo exams and tests with their doctors to check their muscle function, symptom improvement, and specific health markers (like enzyme levels).",[27],"Myositis",[29,30,31,32],"myositis","anti-inflammation","CCR5","Maraviroc","NOT_YET_RECRUITING","2026-06-26",{"date":36,"type":37},"2026-06-30","ACTUAL",{"date":39,"type":21},"2026-09-01",{"date":41,"type":21},"2029-08-31",{"name":43,"class":44},"Chinese University of Hong Kong","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":66,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100587219","phase-1-a-safety-and-efficacy-study-evaluating-ctx112-in-adult-subjects-with-refractory-autoimmune-disease-100587219","NCT06925542","A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease","A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease","Key Inclusion Criteria:\n\n1. Age ≥18 years and \\\u003C 70 years of age.\n2. Subjects must voluntarily sign a written informed consent and be willing and able to comply with all study requirements.\n3. Adequate hematologic, renal, liver, cardiac and pulmonary organ function.\n4. Subjects must agree to use acceptable methods of contraception.\n5. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, contraceptive guidelines, and other study procedures.\n6. Diagnosis of systemic lupus erythematosus (SLE), systemic sclerosis (SSc) or idiopathic inflammatory myopathy (IIM).\n\nFor systemic lupus erythematosus (SLE) subjects:\n\n\\- Diagnosis of SLE by a board-certified rheumatologist that conforms with 2019 ACR\u002FEULAR criteria. For lupus nephritis subjects, active, biopsy-proven proliferative lupus nephritis Class III or IV, either with or without the presence of Class V, and appropriate National Institutes of Health index activity score using the 2018 International Society of Nephrology\u002FRenal Pathology Society criteria.\n\nFor Systemic Sclerosis (SSc) subjects:\n\n\\- Diagnosis of diffuse cutaneous systemic sclerosis (dcSSC) or SSc-ILD that conforms with 2013 ACR\u002FEULAR criteria. Subjects should meet active skin or lung disease criteria.\n\nFor Idiopathic Inflammatory Myopathy (IIM) subjects:\n\n\\- Diagnosis with dermatomyositis (DM), polymyositis (PM) or myositis as part of rheumatologic overlap syndrome, antisynthetase (ASyS), or immune-mediated necrotizing myopathy (IMNM) that conforms with 2017 ACR\u002FEULAR criteria for inflammatory myopathies. Subjects must meet moderate severe, skin, or lung involvement criteria.\n\nKey Exclusion Criteria:\n\n1. Prior anti-CD19 therapy or any gene therapy\u002Fgenetically modified cell therapy.\n2. Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant.\n3. Severe active or history of central nervous (CNS) involvement.\n4. History of a seizure disorder, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar disease or any autoimmune disease with CNS involvement other than SLE, SSc or IIM.\n5. Mixed connective tissue disease with no clear predominant disease.\n6. Presence of study disease manifestations or other conditions that are likely to pose increase safety risks and\u002For confound disease assessments, or pose significant risk to those receiving CAR T cell therapy.\n7. History of primary or secondary immunodeficiency.\n8. Presence or history of certain bacterial, viral or fungal infection.\n9. Malignancy in the last 5 years (with the exception of cancers deemed to be low likelihood for recurrence).\n10. Diagnosis of a genetic disorder associated with bone marrow failure or myelodysplastic syndrome.\n11. History or current diagnosis of catastrophic anti-phospholipid syndrome or anti phospholipid syndrome that requires ongoing anticoagulation.\n12. Pregnant or lactating.\n13. Presence or history of disease requiring treatment that is not compatible with the study protocol; presence or history of other conditions that are not compatible with the study protocol.","70 Years",{"count":55,"type":21},80,[57],"PHASE1","This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).",[60,61,62,63,64,27,65],"SLE (Systemic Lupus)","Lupus Erythematosus, Systemic","Lupus Nephritis","Systemic Sclerosis","Inflammatory Myopathy, Idiopathic","Diffuse Cutaneous Systemic Sclerosis",[67,68,69,62,70,71,72,73,27,74,75,76,77,78,79],"CAR T","Lupus","SLE","Allogeneic","CD19","Cell Therapy","Scleroderma","Systemic sclerosis","Idiopathic Inflammatory Myopathy","Inflammatory Myopathy","Diffused Cutaneous Systemic Sclerosis","Gene Therapy","Autoimmune","RECRUITING","2026-06-11",{"date":83,"type":37},"2026-06-15",{"date":85,"type":37},"2025-03-10",{"date":87,"type":21},"2031-12-31",{"name":89,"class":90},"CRISPR Therapeutics","INDUSTRY",14,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":16,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":105,"conditions":106,"keywords":111,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":4,"leadSponsor":122,"locationsCount":125},"100153996","environmental-risk-factors-for-the-anti-synthetase-syndrome-100153996","NCT01276470","Environmental Risk Factors for the Anti-synthetase Syndrome","Environmental Risk Factors for the Anti-Synthetase Syndrome","* INCLUSION CRITERIA:\n\nThere are no gender or ethnic restrictions to enrollment in the study. Age restrictions for children do apply to enrollment in the study.\n\nThe inclusion criteria for enrollment of myositis subjects are:\n\n1. Diagnosis of myositis based on criteria for possible, probable or definite PM or DM, with or without other connective tissue diseases, documented within 24 months of enrollment (using the most recent diagnosis date to define the 24-month period).\n2. CXR to assess possible ILD and assign the subject to the presumptive anti-synthetase positive or negative category if clinically indicated.\n3. Children must be greater than two years of age.\n4. Able and willing to give informed consent, to complete the questionnaires and to donate blood samples (in case of children greater than 2 years of age but \\\u003C18 years of age, parent\u002Flegal guardian must be willing and able to provide informed consent and child will provide assent according to child s maturity level and understanding).\n\nThe exclusion criteria for myositis subjects are:\n\n1. Cancer-associated myositis (cancer diagnosed within 2 years of the diagnosis of myositis).\n2. Inclusion body myositis.\n3. Myositis that has clearly developed as the result of a drug, toxin or other exposure and has resolved after discontinuation of the exposure to that agent.\n4. Children less than 2 years of age.\n\nThe inclusion criteria for controls are:\n\n1. Friends or, if friends are not available, cousins of the anti-synthetase-positive myositis patient, or, if friends or cousins are not available, volunteers from the general community (such as the NIH Normal volunteer program), race- gender- and age- (within 5 years for minors and within 10 years for adults) matched, and when possible who is living as close as possible to the geographic area of the myositis patient.\n2. Controls should be without a recognized autoimmune disease or ILD.\n3. Able and willing to give informed consent, to complete the questionnaires and to donate blood samples (in case of children greater than 2 years of age but \\\u003C18 years of age, parent\u002Flegal guardian must be willing and able to provide informed consent) and child will provide assent according to child maturity level and understanding).\n\nThe exclusion criteria for all protocol subjects are:\n\n1. Medical illness that in the judgment of the investigators does not allow safe blood draws or other clinical evaluations needed for study participation.\n2. Cognitive impairment.\n3. Not able or willing to give informed assent or consent.\n4. Children less than 2 years of age.\n5. Patients who at their reference date were not in the US or Canada\n6. Individuals currently incarcerated\n\nHIV considerations:\n\nHIV is not an exclusion for affected participants in this study for the two following reasons:\n\n1. It has no impact on study procedures or tests.\n2. It may be one of the viral risk factors we are investigating.",true,"2 Years","100 Years",{"count":103,"type":21},580,"OBSERVATIONAL","Background:\n\n* Like other complex diseases, autoimmune diseases are the result of numerous causes, including genetic and environmental factors. Some researchers believe that people who are susceptible to autoimmune disorders develop them when the body reacts to environmental or other factors by creating white blood cells that attack the body s own tissues, which then progresses to autoimmune diseases. These immune-triggered disorders can overlap with one another to some extent, but most autoimmune diseases have certain distinct triggers.\n* The autoimmune disorder myositis weakens the muscles and may cause other health problems. Environmental exposures associated with myositis include ultraviolet radiation, stressful life events and muscle overexertion, collagen implants, infections such as retroviruses and streptococci bacteria, and certain drugs and chemicals. Some individuals with myositis also produce proteins in the blood called autoantibodies that react with certain parts of the person s own cells, called synthetases, which are involved in making new proteins. A syndrome called the anti-synthetase syndrome, which includes myositis and lung disease, is associated with having the anti-synthetase autoantibodies. Researchers are interested in studying differences in environmental exposures in individuals with myositis. This study is being conducted to determine if persons with the anti-synthetase syndrome have had different environmental exposures before disease onset compared with other patients with myositis who do not have this syndrome and also compared with healthy volunteers.\n\nObjectives:\n\n\\- To determine whether selected infectious and noninfectious environmental exposures are more common in individuals who have myositis with the anti-synthetase syndrome, compared with healthy volunteers.\n\nEligibility:\n\n\\- Individuals who have been diagnosed with myositis (with or without anti-synthetase autoantibodies), and healthy volunteers without autoimmune disorders.\n\nDesign:\n\n* Participants will be screened with a full medical history and physical examination, and will provide blood, urine and house dust samples.\n* Participants will complete questionnaires about their medical history and the types of exposures they have had at work, at home, and elsewhere. Participants who have myositis will also be asked about certain infections, heavy exercise or physical exertion, sun exposure, tobacco and alcohol use, and stressful events prior to being diagnosed with the disease. Healthy volunteers will be asked about the same exposures before the date of diagnosis of disease of the myositis subject to which they have been matched.\n* Participants will receive a kit that contains instructions and a filter to be put onto their vacuum cleaner to collect house dust in the bedroom. This dust will be kept for possible future analyses of infectious or toxic agents based on the other results from the study.\n* Individuals with myositis will have other tests as clinically indicated, including lung function tests and imaging studies.",[27,107,108,109,110],"Dermatomyositis","Polymyositis","Juvenile Dermatomyositis","Juvenile Polymyositis",[112,113,114,115,116,117],"Adult and Pediatric Autoimmune Disease","Antibody","Autoimmune Diseases","Autoimmunity Pathogenesis","Environmental Risk Factors","Natural History",{"date":119,"type":37},"2026-06-12",{"date":121,"type":37},"2011-02-09",{"name":123,"class":124},"National Institute of Environmental Health Sciences (NIEHS)","NIH",8,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100508083","phase-3-a-study-to-understand-how-the-study-medicine-pf-06823859-works-in-people-with-active-idiopathic-inflammatory-myopathies-dermatomyositis-dm-and-polymyositis-pm-100508083","NCT05895786","A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]","A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS)","Inclusion Criteria:\n\n* Male or female adults (≥18 years old or minimum legal adult age as defined per local regulation, whichever is greater)\n* Active dermatomyositis (DM) or polymyositis (PM) with age of onset\n\n  * 18 years old.\n* Must be receiving a stable dose of standard of care (SOC) background medications at the time of enrollment.\n\nExclusion Criteria:\n\n* Myositis due to non-Idiopathic inflammatory myopathies (non-IIM)\n* Existing diagnosis of inclusion body myositis (IBM)\n* Presence of immune-mediated necrotizing myositis (IMNM)\n* Myositis with end-stage organ involvement\n* Active bacterial, viral or fungal infections or hospitalizations for serious infections within 60 days prior to enrollment\n* History of recurrent bacterial, viral, fungal, mycobacterial or other infections\n* Clinically significant finding on a chest x-ray\n* Have cancer or a history of cancer within 5 years of screening\n* Significant current or prior disease conditions that may interfere with the response to or safety of the study medicine, including but not limited to:\n* history of major organ transplant\n* acute coronary syndrome or any history of significant cerebrovascular disease within 24 weeks of screening\n* preexisting demyelinating disorder such as multiple sclerosis, or other severe neurological disorder\n* major surgery within 4 weeks of screening, or scheduled to occur during the study, excluding diagnostic surgery\n* previous treatment with total lymphoid irradiation\n* history of any lymphoproliferative disorder such as Epstein Barr Virus, history of lymphoma, leukemia, or symptoms of current lymphatic or lymphoid disease\n* Clinically significant depression, suicidal ideation, or previous history of suicidal behaviors\n* Other medical or laboratory abnormality that may increase the risk of study participation\n* Previous administration with an investigational product (drug or vaccine) within 30 days or of the first dose of study medicine\n* Current use or incomplete appropriate washout period of any prohibited medication(s) or known exposure to anti-interferon beta (PF-06823859) or any type of anti-interferon beta therapy\n* Prior SOC medication that does not fulfill the criteria\n* Certain laboratory results from screening assessments that may interfere with study participation.\n* Investigator site staff directly involved in the conduct of the study and their family members, site staff and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members",{"count":134,"type":21},318,[136],"PHASE3","The purpose of the study is to understand how the study medicine PF-06823859 (dazukibart) works in people with idiopathic inflammatory myopathies (DM and PM). These disorders cause inflammation that weakens the muscles that are important for movement and may also cause skin rash in people with DM.\n\nThis study is seeking participants who:\n\n* Are 18 years of age or older or minimum legal adult age as defined per local regulation, whichever is greater\n* Have active DM or active PM.\n* Are receiving a stable dose of 1 corticosteroid taken by mouth and\u002For 1 traditional immunosuppressant.\n\n  * Note: Corticosteroids and immunosuppressants are medicines that help reduce inflammation and may signal to the immune system not to attack the body.\n\nDermatomyositis (DM) is a rare disease that causes muscle inflammation that results in muscle weakness and low muscle stamina. Patients with DM have a characteristic skin rash. Polymyositis (PM) is a rare disease that involves mainly muscle inflammation resulting in muscle weakness, that can sometimes be painful. Patients with DM and PM may have trouble going up the steps, walking or getting to a standing position.\n\nSome of the participants will receive the study medicine (dazukibart) and some will receive placebo (which is similar to study medicine but contains no medicine in it).\n\nThe study medicine or placebo will be given as an intravenous (IV) infusion (directly into the veins), which takes about 1 hour; every 4 weeks from Day 1 to Week 48 of the study. Both dazukibart and placebo and will be given at the study site.\n\nThe study will compare the experiences of people receiving study medication to those of the people who do not. This will help to see if dazukibart is safe and effective.\n\nParticipants will take part in this study for about 13 months. During this time, participants will have 15 study visits. These visits will be performed at the study site.",[27],[107,108],"2026-05-29",{"date":142,"type":37},"2026-06-01",{"date":144,"type":37},"2023-05-20",{"date":146,"type":21},"2027-07-28",{"name":148,"class":90},"Pfizer",146,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":161,"conditions":162,"keywords":170,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":193},"100592260","phase-2-allonk-an-allogeneic-non-genetically-modified-cord-blood-derived-nk-cell-therapy-in-combination-with-rituximab-studied-in-relapsing-forms-of-b-cell-dependent-rheumatologic-diseases-100592260","NCT06991114","AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.","An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases","For Subjects with Refractory Rheumatoid Arthritis (RA):\n\n* Documented diagnosis of RA, meeting the 2010 ACR\u002FEULAR classification criteria.\n* Rheumatoid Factor (RF) or Anti Citrullinated Protein Antibody (ACPA) positive.\n* High-sensitivity C-reactive protein (hs-CRP) \\> 3 mg\u002FL or Erythrocyte Sedimentation Rate (ESR) \\> 28 mm\u002Fhr.\n* Have had prior treatment for a period of at least 12 weeks with a biologic disease modifying anti-rheumatic drug and were deemed refractory by the treating physician.\n* Minimum of six swollen joint counts (SJC) and six tender joint counts (TJC) according to joint assessment.\n\nFor subjects with Sjögren's Disease (SjD)\n\n* Prior diagnosis of Primary SjD as per 2016 ACR\u002FEULAR criteria with confirmatory diagnosis in the 24 weeks preceding screening.\n* Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) \\> 6.\n* Salivary Flow Rate \\> 0.1 mL\u002Fmin on stimulation.\n\nFor subjects with Idiopathic Inflammatory Myopathies (IIMs)\n\n* Presence of a positive autoantibody (ANA \\>1:80 or RNP or SSA\u002FSSB or other myositis specific autoantibodies.\n* Refractory IIM as defined by inadequate response\u002Fintolerance to at least 3 months of glucocorticoids and\u002For at least one other immunosuppressive.\n* Muscle biopsy or muscle MRI to confirm IIM diagnosis, where applicable, within 12 months prior to enrollment.\n\nFor Subjects with Systemic Sclerosis (SSc)\n\n* Diagnosis of SSc in accordance with the ACR\u002FEULAR 2013 classification.\n* Modified Rodnan skin score (mRSS) \\> 10.\n* Initial confirmatory diagnosis within 8 years of screening.\n* Refractory SSc as defined by inadequate response\u002Fintolerance to at least 3 months of glucocorticoids and\u002For at least one other immunosuppressive.",{"count":158,"type":21},90,[160],"PHASE2","A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.",[163,164,165,166,167,27,73,168,169],"Refractory Rheumatoid Arthritis (RA)","Idiopathic Inflammatory Myopathies (IIMs)","Systemic Sclerosis (SSc)","Rheumatoid Arthritis (RA","IIM","Sjogren Syndrome","Sjogrens Disease",[171,172,173,63,174,175,72,176,177,178,179,180,181,182,183],"Refractory Rheumatoid Arthritis","AlloNK","Idiopathic Inflammatory Myopathies","Sjögren's Disease","Refractory RA","Allogeneic NK Cells","Allogeneic Cell Therapy","non-genetically modified","rituximab","cord blood cells","ADCC enhancement","outpatient","community","2026-05-20",{"date":186,"type":37},"2026-05-22",{"date":188,"type":37},"2025-07-09",{"date":190,"type":21},"2029-01",{"name":192,"class":90},"Artiva Biotherapeutics, Inc.",52,{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":201,"targetDuration":203,"studyType":104,"phases":4,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":45},"100635402","muscle-imaging-project-using-anatomopathology-and-full-field-optical-coherence-tomography-100635402","NCT07552220","Muscle Imaging Project Using ANatomopathology and Full Field Optical Coherence Tomography","PIMANT","Inclusion Criteria:\n\n* Patient \\> 18 years old ans has given his oral consent\n* Patient who biospies are performed as part of care\n\nExclusion Criteria:\n\n* Patient \\\u003C 18 years old",{"count":202,"type":21},20,"1 Day","Myositis is an inflammatory disease of the skeletal muscles that can be caused by infections, autoimmune diseases, or medications. Early diagnosis of these conditions is essential for optimal treatment. Anatomic pathology is the conventional method used to analyze muscle lesions, but it requires several weeks to obtain results. Full-field optical coherence tomography (OCT), a non-invasive imaging technique, could offer advantages in terms of speed and resolution for visualizing muscle inflammation.\n\nThis research project compares histological pathology and full-field OCT for the analysis of muscle biopsies from healthy individuals and patients suspected of having myositis. The aim of this study is to establish an OCT reference standard by analyzing control muscle biopsies and then comparing muscle inflammation in confirmed cases of myositis. The advantages and limitations of both methods will also be evaluated.",[27,206],"Health Adult Subjects",[208,209,210,211],"anatomopathology","Full field optical coherence tomography","muscle biopsies","Myositis and healthy patients","2026-04-20",{"date":214,"type":37},"2026-04-27",{"date":216,"type":21},"2026-04",{"date":218,"type":21},"2028-12",{"name":220,"class":44},"Centre Hospitalier de Mâcon",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":99,"sex":16,"minAge":17,"maxAge":228,"enrollmentInfo":229,"targetDuration":203,"studyType":104,"phases":4,"briefSummary":231,"conditions":232,"keywords":239,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":45},"100631615","muscle-health-measurements-using-electrical-impedance-myography-100631615","NCT07502989","Muscle Health Measurements Using Electrical Impedance Myography","Convenient Quantification of Myopathic Change in Muscle Via Electrical Impedance Myography","Inclusion Criteria:\n\n* Ages 18-89\n* Evidence of a primary myopathic condition as determined by detailed chart review, including results of genetic testing, serological data, or previous muscle biopsy\n\nExclusion Criteria:\n\n* Inability to lie flat or history of claustrophobia\n* \\>1+ lower extremity edema\n* Presence of multiple other pathologies affecting lower extremity muscles to be studied\n* Pregnancy\n* Contraindications for MRI scanning - e.g. MRI incompatible pacemaker, deep brain stimulator, or lower extremity hardware\n* Contraindications to undergo DXA Scan\n\n  * Any studies\u002Fscans with a radioisotope within the past 15 days\n  * Any imaging with radiographic contrast in the past 7 days\n  * Weight greater than 450 lbs\n  * Calcium supplements or antacids containing calcium in the past 24 hours\n* Severe obesity with BMI \\> 35 kg\u002Fm2, given difficulties fitting in MRI scanner and impact of severe obesity on EIM data\n* Chronic skin conditions with ulcerations which would interfere with EIM electrode contact or be uncomfortable for the participant","89 Years",{"count":230,"type":21},150,"This study is being done to further develop a device, the mScan, to measure muscle health as compared to measurements of muscle health using MRI (magnetic resonance imaging). This device is held against the skin and uses Electrical Impedance Myography (EIM). EIM uses a very small, noninvasive (e.g. no needles), brief (about 6 seconds), and painless electrical current to measure the muscle. The investigators will look at how the mScan predicts the muscle measurements seen on MRI in people with and without muscle disease. The investigators hope that this can be used in the future as a quick, convenient and less time-consuming way than MRI to assess muscle health. This could be used to measure how well treatments for different muscle disorders are working over a period of time.",[233,234,27,235,236,237,238],"Myopathy","Muscular Dystrophies","Myofibrillar Myopathy","Congenital Myopathy","Distal Myopathy","Myopathies",[240,233,241,242,243,244,245],"Muscle Health","Device","Healthy control","MRI","Electrical Impedance Myography","EIM","2026-03-30",{"date":248,"type":37},"2026-04-03",{"date":250,"type":37},"2025-04-09",{"date":252,"type":21},"2027-09",{"name":254,"class":44},"Beth Israel Deaconess Medical Center",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":16,"minAge":263,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":267,"conditions":268,"keywords":272,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":45},"100458576","clinico-biological-collection-to-investigate-the-physiopathology-of-systemic-autoimmune-diseases-100458576","NCT05251415","Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases","Constitution of a Collection of Biological Samples With the Aim of Carrying Out Clinico-biological and Pathophysiological Investigations of Systemic Autoimmune Diseases","ESSAi","Inclusion Criteria:\n\n* Patients with rare systemic autoimmune diseases (lupus, scleroderma, myositis for example),\n* Patients with atypical presentations of documented or probable systemic autoimmune diseases,\n* Patients receiving, or likely to receive new, innovative therapies (new molecule on the market, gene therapy, cell therapy, etc.).\n\nExclusion Criteria:\n\n* Known anemia and hemoglobin \\\u003C10 g \u002F dl\n* Patients under protective supervision (guardianship, curators)\n* Pregnant or breastfeeding woman","6 Years","99 Years",{"count":266,"type":21},3000,"The aim of this project is to start a biological and clinical collection of patients presenting systemic autoimmune disease. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies",[269,73,27,270,271],"Lupus Erythematosus","Vasculitis","Inflammatory Bowel Diseases",[273,274,275,29,276,271,277],"systemic autoimmune diseases","scleroderma","lupus","vasculitis","new therapies","2026-03-16",{"date":280,"type":37},"2026-03-17",{"date":282,"type":37},"2022-04-04",{"date":284,"type":21},"2032-04-04",{"name":286,"class":44},"University Hospital, Toulouse",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":295,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":298,"conditions":299,"keywords":306,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":45},"100621706","mihra---patient-rooted-insights-for-shaping-myositis-science-prisms-100621706","NCT07374107","MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)","MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS) - A Qualitative Study of Patient-voiced Research Priorities Across Rare Myositis Diseases","MIHRA-PRISMS","Inclusion Criteria:\n\n* Ability to provide informed consent\n* Have a clinician diagnosis of an idiopathic inflammatory myopathy or be a care partner or parent of a person living with an idiopathic inflammatory myopathy.\n* Participants who may have signed up through the MIHRA Patient Contact Registry https:\u002F\u002Fmihrafoundation.org\u002Fmihra-programs\u002Fmihra-patient-contact-registry\u002F\n\nExclusion Criteria:\n\n* Under the age of 7 years old\n* Do not have a diagnosis of an inflammatory myopathy","7 Years",{"count":297,"type":21},700,"Myositis diseases are each rare diseases. As in other rare diseases, people living with myositis diseases face physical and psychosocial challenges that may not be recognized in current research priorities. The PRISMS study is a global investigation that collects patient perspectives through (mostly online) methods of open-ended questions, community forums and survey to identify the most pressing research concerns as identified by patients. Findings will be analyzed to create a patient-voiced set of research priorities that can guide the direction of research and help inform funding decisions across myositis diseases.\n\nPotential participants can express interest via https:\u002F\u002Fmihrafoundation.org\u002Fmihra-programs\u002Fmihra-patient-contact-registry\u002F",[300,167,27,76,107,301,302,303,108,304,305,109],"IBM","Dermatomyositis, Juvenile","Anti-synthetase Syndrome","Immune-Mediated Necrotizing Myopathy","Inclusion Body Myositis","Juvenile Myositis",[29,307,308,309,310,311,312,313,314],"rare diseases","patient priorities","patient engagement","patient initiated","patient research partners","qualitative research","mixed methods research","research priorities","2026-01-20",{"date":317,"type":37},"2026-01-28",{"date":319,"type":37},"2025-06-25",{"date":321,"type":21},"2030-12",{"name":323,"class":44},"Myositis International Health & Research Collaborative Alliance Foundation",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":45},"100573006","neuromuscular-complications-of-mek-inhibitors-a-french-case-series-and-a-systematic-review-of-the-literature-100573006","NCT06740656","Neuromuscular Complications of MEK Inhibitors: a French Case Series and a Systematic Review of the Literature","Inclusion Criteria:\n\n* Patients with neuromuscular complications of MEK inhibitors used alone or in combination\n* Age \\> 18 years\n\nExclusion Criteria:\n\n* Refusal of data collection",{"count":331,"type":21},5,"MEK inhibitors (trametinib, cobimetinib, selumetinib or binimetinib) have been used since 2016 to treat metastatic melanoma, by targeting the MAPK pathway Neuromuscular complications (neuropathy, myasthenia or myositis) have been reported in patients treated with MEK inhibitors.\n\nWith the growing use of these new oncology therapies, neurologists, oncologists and other clinicians are likely to be increasingly confronted with MEK inhibitor-induced neuropathy, myasthenia or myositis.\n\nYet, so far, these complications have only been documented in a few single case reports.\n\nOur aim was to characterize the neuromuscular complications associated with MEK inhibitors used either alone or in combination.",[27,334,335,336,337],"Myasthaenia Gravis","Neuropathy","Guillain Barré Syndrome","Parsonage Turner Syndrome","2025-02-16",{"date":340,"type":37},"2025-02-18",{"date":342,"type":21},"2025-03-01",{"date":344,"type":21},"2026-01-01",{"name":346,"class":44},"Central Hospital, Nancy, France",{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":355,"targetDuration":357,"studyType":104,"phases":4,"briefSummary":358,"conditions":359,"keywords":360,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":45},"100561250","investigation-of-the-validity-reliability-and-responsiveness-of-the-bety-bq-in-myositis-100561250","NCT06587724","Investigation of the Validity, Reliability, and Responsiveness of the BETY-BQ in Myositis","Investigation of the Validity, Reliability, and Responsiveness of the BETY-Biopsychosocial Questionnaire in Individuals Diagnosed with Myositis","BETY-BQ","Inclusion Criteria:\n\n* Diagnosis of myositis\n* To be over 18 years old\n* Consent of the participant\n\nExclusion Criteria:\n\n* Uncontrolled\u002Fother clinically significant disease (chronic obstructive pulmonary disease, congestive heart failure, endocrine system diseases, neurological, psychological diseases, etc.) individuals with a diagnosis,\n* Pregnant individuals,\n* Individuals with malignancy",{"count":356,"type":21},100,"3 Months","Individuals diagnosed with myositis have skin, joint, and visceral organ involvement together with proximal muscle weakness, impaired physical function, sexual function, and quality of life also affect individuals psychosocially. Increased anxiety-depression-anxiety problems are observed in individuals, and many factors contributing to these conditions are reported. Therefore, while holistic evaluation of individuals, including these factors, gains importance, more information on how the quality of life changes during the disease is required. There is a need for tools to evaluate these characteristics in individuals disease management and treatment process.\n\nThe cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY) is an innovative exercise model based on physical exercise and an example of a biopsychosocial approach developed in patients with rheumatism. The BETY-Biopsychosocial Questionnaire (BETY-BQ) was created by repeated statistics of the improvement characteristics reported by individuals who participated in BETY sessions for many years. The BETY-BQ holistically evaluates many biopsychosocial characteristics of the individual, such as pain, coping skills, functionality, mood, sociability, sexuality, and sleep. Therefore, there is a need for scales that holistically evaluate the symptoms mentioned in myositis disease. Since the BETY-BQ can assess biopsychosocial characteristics quickly and its structure was created with the feedback of individuals with chronic disease, it aimed to examine its validation in this disease group.\n\nThis study, which the investigators planned to contribute to this field, aims to investigate BETY-BQ\\^s validity, reliability, and responsiveness in individuals diagnosed with myositis.",[27],[29,361,362,353,363,364],"biopsychosocial model","validity and reliability","muscle strenght","pain","2024-09-12",{"date":367,"type":37},"2024-09-19",{"date":369,"type":37},"2024-07-24",{"date":371,"type":21},"2026-12-31",{"name":373,"class":44},"Hacettepe University"]